Baidu
map

J Eur Acad Dermatol Venereol:局部使用Thiamidol VS. 4%氢醌霜治疗面部黄褐斑的疗效和安全性

2021-10-17 MedSci原创 MedSci原创

黄褐斑的治疗十分困难,而且经常复发。硫胺素是一种新的强效酪氨酸酶抑制剂,是一种有效的祛除黄褐斑的药妆。近日,发表于J Eur Acad Dermatol Venereol的随机、评估者盲法对照研究比较

黄褐斑的治疗十分困难,而且经常复发。硫胺素是一种新的强效酪氨酸酶抑制剂,是一种有效的祛除黄褐斑的药妆。近日,发表于J Eur Acad Dermatol Venereol的随机、评估者盲法对照研究比较了外用0.2%噻米诺与4%氢醌治疗面部黄褐斑的疗效和耐受性。

研究共纳入了50名患有面部黄褐斑的女性,随机分配到每天两次涂抹双层0.2%硫胺素或在睡前涂抹4%氢醌霜,持续90天。两组都接受有色防晒霜(防晒系数60,PPD20)。主要结果是与基线改良后的黄褐斑面积指数(mMASI)得分的变化。次要结果是患者生活质量的改善[黄褐斑生活质量指数(MELASQoL)]、色度测量和全球美学改善量表(GAIS)评估。

 

结果,氢醌组的一名参与者没有完成研究(与不良反应无关)。参与者的平均(SD)年龄为43(6)岁,86%的患者为III-IV型。两组都表现出mMASI、MELASQoL和色彩对比分数的下降(P<0.01)。噻米诺的mMASI评分平均[95%置信区间(CI 95%)]减少了43%(35-50%),氢醌减少了33%(23-42%)。各组之间在mMASI、MELASQoL、色度对比和GAIS评分的降低方面没有差异(P≥0.09)。GAIS分析的结果是,噻米多组参与者的改善率为84%(CI:95% 67-97%),氢醌组参与者的改善率为74%(CI:95% 61-93%)。硫胺素组只有轻微的不良反应,但有两名(8%)参与者出现了过敏性接触性皮炎。

综上所述,该研究结果表明,使用0.2%的噻米多尔所取得的黄褐斑改善效果与4%的氢醌霜没有区别。对于耐受性差或使用氢醌治疗失败的黄褐斑患者来说,可以考虑使用硫胺素作为合适的选择。

 

原始出处:

 

P B Lima, et al., Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1881-1887. doi: 10.1111/jdv.17344.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703535, encodeId=ce911e0353574, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Wed Jul 06 19:39:54 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651993, encodeId=90741651993c8, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Sep 11 00:39:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721089, encodeId=a84c1e210893e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Jul 10 15:39:54 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406109, encodeId=d6b614061098b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Oct 19 10:39:54 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-07-06 tongyongming
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703535, encodeId=ce911e0353574, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Wed Jul 06 19:39:54 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651993, encodeId=90741651993c8, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Sep 11 00:39:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721089, encodeId=a84c1e210893e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Jul 10 15:39:54 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406109, encodeId=d6b614061098b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Oct 19 10:39:54 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-09-11 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703535, encodeId=ce911e0353574, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Wed Jul 06 19:39:54 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651993, encodeId=90741651993c8, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Sep 11 00:39:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721089, encodeId=a84c1e210893e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Jul 10 15:39:54 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406109, encodeId=d6b614061098b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Oct 19 10:39:54 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703535, encodeId=ce911e0353574, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Wed Jul 06 19:39:54 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651993, encodeId=90741651993c8, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Sun Sep 11 00:39:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721089, encodeId=a84c1e210893e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Jul 10 15:39:54 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406109, encodeId=d6b614061098b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Oct 19 10:39:54 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 chg122

相关资讯

Dermatol Surg:氨甲环酸联用微针疗法可有效治疗黄褐斑

黄褐斑是一种常见的、复发性的、难治性的面部色素沉着,导致美容效果不佳。氨甲环酸(TA)已用于全身和局部色素沉着的清除。近日,发表于Dermatol Surg的一项分脸、前瞻性、随机、开放标签的研究评估

J Cosmet Dermatol:中药调理霜可有效调理黄褐斑

黄褐斑是一种后天性的、常见的面部色素沉着症。虽然目前治疗方法很多,但疗效一般。为了研究一种含有中草药混合物的膏药治疗黄褐斑的安全性和有效性。

J Drugs Dermatol:皮秒激光治疗是一种安全有效的治疗黄褐斑的方法

黄褐斑是一种常见的疾病,患者面部出现色素沉着的斑块和斑片,被认为是由于阳光照射和激素的贡献造成的,但其发病机制还不完全清楚。激光已被用于治疗黄褐斑,并取得了不同程度的成功。本研究旨在探究一种新型皮秒激

Dermatol Surg:皮内注射和微针注射氨甲环酸都可有效且安全的治疗黄褐斑

黄褐斑是一种获得性色素沉着的皮肤疾病。氨甲环酸(TXA)通过干扰血浆蛋白原-血浆蛋白途径防止紫外线辐射引起的黄褐斑的色素沉着。近日,发表于Dermatol Surg的一项研究评估了皮内注射TXA与微针

Dermatol Surg:皮秒亚历山大激光治疗亚洲人难治性黄褐斑的疗效

黄褐斑的治疗仍十分困难,从理论上讲,皮秒脉冲激光能快速地打破和清除表皮和真皮的黑色素。近日,发表于Dermatol Surg的一项前瞻性研究探究了皮秒亚历山大激光器与衍射透镜阵列和平光镜治疗黄褐斑的疗

J Cosmet Dermatol:预防黄褐斑,防晒霜必不可少

长期以来,防晒霜作为辅助药物一直是治疗黄褐斑不可缺少的一部分。以往的研究均未评价单独使用防晒霜对黄褐斑的改善作用。本研究旨在探究广谱防晒霜与防晒因子19和PA+++作为唯一的药物对黄褐斑的改善作用。

Baidu
map
Baidu
map
Baidu
map